scholarly journals The Effect of Prognostic Factors and Adjuvant Radiotherapy on Survival in Patients with High-Grade Early-Stage Endometrial Cancer: A Retrospective Clinical Study

2019 ◽  
Vol 25 ◽  
pp. 2811-2818
Author(s):  
Ercan Yilmaz ◽  
Simay Gurocak ◽  
Rauf Melekoglu ◽  
Isil Koleli ◽  
Simge Faydali ◽  
...  
Keyword(s):  
Endometrial Cancer ◽  
Prognostic Factors ◽  
Clinical Study ◽  
Adjuvant Radiotherapy ◽  
Early Stage ◽  
High Grade ◽  
Retrospective Clinical Study ◽  
Early Stage Endometrial Cancer

scholarly journals Adjuvant radiotherapy in early stage endometrial cancer

2011 ◽  
Vol 57 (4) ◽  
pp. 431-435
Author(s):  
Antonio Carlos Zuliani ◽  
AureaAkemi Cairo ◽  
Sérgio Carlos Barros Esteves ◽  
Carla Cristina dos Santos Watanabe ◽  
Maércio de OliveiraCunha ◽  
...  
Keyword(s):  
Endometrial Cancer ◽  
Adjuvant Radiotherapy ◽  
Early Stage ◽  
Early Stage Endometrial Cancer

scholarly journals Adjuvant radiotherapy in early stage endometrial cancer

2011 ◽  
Vol 57 (4) ◽  
pp. 438-442 ◽  
Author(s):  
Antonio Carlos Zuliani ◽  
Aurea Akemi Cairo ◽  
Sérgio Carlos Barros Esteves ◽  
Carla Cristinados Santos Watanabe ◽  
Maércio de Oliveira Cunha ◽  
...  
Keyword(s):  
Endometrial Cancer ◽  
Adjuvant Radiotherapy ◽  
Early Stage ◽  
Early Stage Endometrial Cancer

Prognostic significance of immunohistochemical markers in endometrial cancer treated with chemotherapy

2009 ◽  
Vol 27 (15_suppl) ◽  
pp. e16551-e16551
Author(s):  
S. R. Lord ◽  
N. Vasudev ◽  
S. Knight ◽  
V. Speirs ◽  
G. Hall
Keyword(s):  
Endometrial Cancer ◽  
Prognostic Factors ◽  
Poor Prognosis ◽  
Early Stage ◽  
Good Prognosis ◽  
Serous Carcinoma ◽  
Positive Staining ◽  
Endometrioid Adenocarcinoma ◽  
Similar Frequency ◽  
Early Stage Endometrial Cancer

e16551 Background: The proportion of patients receiving chemotherapy for endometrial cancer is increasing both in the adjuvant and advanced setting. The literature describes many prognostic immunohistochemical factors in early stage endometrial cancer, the majority of whom will not receive chemotherapy. The aim of this study was to describe the biomarker expression for endometrial tumours treated with chemotherapy and to assess what constitutes a favourable and unfavourable profile for this patient group. Methods: For a subset of patients with either endometrioid, serous or a mixed mullerian morphology treated with chemotherapy at our centre between 1996 and 2008 an immunohistochemical profile of 14 biomarkers was studied (ERα, Erβ1, Erβ2, PR, PRB, P53, Rb, E-cad, MDM2, MIB-1, E2F1, p16, p13, and p21). A univariate analysis using cox regression of potential prognostic factors was then carried out. Results: In total 199 patients received chemotherapy for endometrial cancer over the 12 year period studied. Two year survival from commencement of chemotherapy for patients receiving adjuvant treatment was 45.2% and palliative treatment 28.1%. The commonest histological subtypes were endometrioid adenocarcinoma (40%), serous carcinoma (24.1%) and mixed mullerian tumours (14.6%). For the subset of 35 patients 38.2% of patients had positive immunohistochemical staining for ERα, 53% for PR, 73.5% for p16, and 94% for E2F1. Good prognosis was predicted by the strength of staining for E2F1 (HR 0.757, CI 0.216/0.902, p = 0.025) and poor prognosis by p16 (HR 1.470, CI 1.040/2.077, p = 0.029). Conclusions: Positive staining for ERα and PR was of similar frequency to previous studies of early stage endometrial cancer and did not significantly influence prognosis. Good prognosis correlated with E2F1 expression and poor prognosis with p16. A greater proportion of patients had serous morphology compared to published series of early stage endometrial cancer. Further study of prognostic factors in larger numbers of patients and built into prospective randomised trials may allow the creation of a prognostic model and guide the development of future clinical trials of targeted therapy. No significant financial relationships to disclose.

Adjuvant radiotherapy and survival outcomes in early-stage endometrial cancer: A multi-institutional analysis of 608 women

2006 ◽  
Vol 103 (2) ◽  
pp. 661-666 ◽  
Author(s):  
O. Kenneth Macdonald ◽  
William T. Sause ◽  
R. Jeffrey Lee ◽  
Christopher M. Lee ◽  
Mark K. Dodson ◽  
...  
Keyword(s):  
Endometrial Cancer ◽  
Adjuvant Radiotherapy ◽  
Early Stage ◽  
Institutional Analysis ◽  
Survival Outcomes ◽  
Early Stage Endometrial Cancer

Impact of adjuvant treatment on outcome in high-risk early-stage endometrial cancer: a retrospective three-center study

2019 ◽  
Vol 29 (1) ◽  
pp. 133-139
Author(s):  
Limor Helpman ◽  
Tamar Perri ◽  
Natalie Lavee ◽  
Nasreen Hag-Yahia ◽  
Hila Amichay Chariski ◽  
...  
Keyword(s):  
Endometrial Cancer ◽  
High Risk ◽  
Adjuvant Treatment ◽  
Early Stage ◽  
Stage I ◽  
Adjuvant Radiation ◽  
High Grade ◽  
Pelvic Radiation ◽  
Wide Range ◽  
Early Stage Endometrial Cancer

ObjectiveHigh grade and non-endometrioid endometrial cancers carry a poor prognosis, and the lack of randomized prospective data has led to a wide range of practice regarding adjuvant therapy. The objective of this study was to evaluate the outcomes of different treatment strategies in patients with high-risk, early-stage endometrial cancer.MethodsPatients with high-grade endometrioid, serous endometrial cancer and carcinosarcoma diagnosed between 2000 and 2012 were identified from databases in three gynecologic oncology divisions, in Toronto and in Israel. Adjuvant treatment practices differed across the centers, creating a heterogeneous cohort. A comparison of stage I patients stratified by adjuvant treatment was undertaken. Log-rank tests and Cox proportional hazards models were employed to compare recurrence and survival across treatment groups.Results490patients with high risk endometrial cancer were identified, among them 213 patients with stage I disease. Israeli patients received more chemotherapy (41% vs 10% in stage I disease; P<0.001) than patients in Toronto. Chemotherapy was not associated with improved disease-free, disease-specific or overall survival, nor was it associated with fewer distant recurrences (50% vs 54%). Radiation was also not associated with improved recurrence or survival, nor did it affect the pattern of recurrence. On Cox multivariable analysis, neither radiation treatment nor chemotherapy were significantly associated with outcome (HR for recurrence, 0.72 for pelvic radiation (P=0.46) and 1.99 for chemotherapy (P=0.09); HR for death, 0.67 for pelvic radiation (P=0.29) and 1.03 for chemotherapy (P=0.94)).ConclusionsIn this retrospective analysis, neither adjuvant radiation nor chemotherapy were associated with improved outcome in stage I, high risk endometrial cancer.

Sign in / Sign up

Export Citation Format

Share Document